<DOC>
	<DOCNO>NCT00517569</DOCNO>
	<brief_summary>The purpose study assess safety GX-12 gene therapy combine HAART HIV-1 infect patient investigate efficacy value plasma viral load CD4 count HIV-1 specific IFN-gamma express T-lymphocytes</brief_summary>
	<brief_title>Gene Therapy With GX-12 Combination With HAART HIV-1 Infected Patients</brief_title>
	<detailed_description>Currently , management HIV infection AIDS mainly do antiviral chemotherapy inhibits reverse transcriptase proteolytic enzyme . The HAART ( highly active antiretroviral therapy ) indeed succeed extraordinary decrease mortality increase life expediency AIDS patient . However , significant limitation ( example , treatment fatigue , side effect , emergency resistant , high medical cost , etc. ) . Recently , number bioresearch immunotherapy overcome limitation current medication . GX-12 genetic use naked DNA human IL-12 mutant immune adjuvant . GX-12 design vaccinate individual HIV antigen , result enhance HIV specific immunity expand broadly immune response nonspecifically . In study , safety efficacy GX-12 investigate .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Aged 18 50 year HIV1 type B infect asymptomatic patient Patient receive HAART le 6 month accord standard management guideline reach aviremia Patient appropriate immunity ( i.e. , CD4 count &gt; =400cells/ul SI &gt; 3 CD4+ Tcell proliferation vitro assay ) Patient negative HBV HCV Woman childbearing use contraceptive least 3 month study entry Patients give write consent Patient receive investigational drug participate study within 30 day study Patient experience hypersensitivity drug ( example : plasmid DNA , etc ) Patient receive immunosuppressant Patient receive HIV vaccine Patient receive interleukin ( ) Patient experience opportunistic infection define AIDS study Patient severe recurrent diarrhea vomit Patient clinically significant acute chronic liver dysfunction , kidney dysfunction , hematological disorder , endocrine disorder , immune disorder , heart disease , infection , etc . Patient malignant tumor ( ) Patient alcohol drug abuse Patient potential harm due drug interaction HAART Woman pregnancy ( positive pregnancy test ) beast feed Patient appropriate investigator 's discretion , specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Gene Therapy</keyword>
	<keyword>GX-12</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Interleukin</keyword>
	<keyword>AIDS</keyword>
	<keyword>HIV-1 type B infection</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>